Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.33 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21159142 | 0.88 | RET (0.36) | RETPIK3CDPIK3R1HSD11B1SMN1; SMN2 | |
| SCHEMBL20071313 | 0.82 | RET (0.34) | RETNPC1RAB9AKMT2A | |
| SCHEMBL20148604 | 0.78 | RET (0.33) | RETPIK3CD | |
| SCHEMBL22031273 | 0.78 | HSD11B1 (0.39) | RETPIK3CDHSD11B1SMN1; SMN2KMT2A | |
| SCHEMBL21159143 | 0.76 | RET (0.31) | RET | |
| SCHEMBL22031235 | 0.76 | HSD11B1 (0.38) | RETHSD11B1SMN1; SMN2 | |
| SCHEMBL20160411 | 0.75 | PIK3CD (0.41) | RETPIK3CDHSD11B1SMN1; SMN2KMT2A | |
| SCHEMBL22812224 | 0.74 | HSD11B1 (0.36) | RETHSD11B1SMN1; SMN2KMT2A | |
| SCHEMBL23555271 | 0.73 | RET (0.35) | RETPIK3CDPIK3R1HSD11B1SMN1; SMN2 | |
| SCHEMBL24767229 | 0.73 | HSD11B1 (0.42) | HSD11B1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10555944-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ELI LILLY AND COMPANY (US) | 2020-02-11 | — | — | US | disclosed |
| US-20180134702-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134702-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | RET 1/4885PIK3CD 1191/4885PIK3R1 1473/4885 |
| US-10555944-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | RET 1/4885PIK3CD 1191/4885PIK3R1 1473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.